Author, date and country | Patient group | Study type (level of evidence) | Outcomes | Key results | Study Weaknesses |
---|---|---|---|---|---|
Ricard-Hibon, A, Lecoules N, Jacquin L et al 2020 France | 351 patients over 18 years of age with moderate to severe pain due to limb trauma. 178 received inhaled Methoxyflurane (m)and standard analgesic treatment (SAT) and and 173 received placebo with SAT | Phase 3b Randomised, double-blind, multi-centre, open-label, placebo-controlled conducted across 8 emergency departments | safety | Most adverse events were of mild (111/147) intensity | assessment and treatment bias (according to investigators' choice) |
efficacy | Median time to pain relief 35 minutes (95% CI 28-62) with most pro-nounced effect in patients with severe pain p<0.001 | ||||
satisfaction with use | Increased satis-faction for pa-tient, nurse and physician (p < 0.001) | ||||
Coffey F, Dissmann P, Mirza K, Lomax M 2016 UK | 204 adults over 18 years of age, with minor limb trauma (fractures, dislocations, burns, contusions, lacerations) 103 methoxyflurane vs 101 placebo group | Phase 3, randomised double blind, multi centre, placebo-controlled across 6 Emergency departments | safety | (mostly dizziness/headache) were reported by 42.2% of patients receiving methoxyflurane and 14.9% of patients receiving placebo; none caused withdrawal and the majority were mild and transient. | Unclear as to why a pain score of up to 7 was included and not higher.Limited clinical laboratory sampling to identify if any hepatic or nephrotoxicity present post use |
satisfaction with use | 'Excellent', 'Very Good' or 'Good' by 77.6% of patients, 74.5% of physicians and 72.5% of nurses | ||||
Mercandante 2019 Italy | 270 adults over age 18 moderate -severe pain minor single trauma (fracture, dislocation, crush injury or contusion | Phase 3b randomised, open-label, multi-centre, active-controlled, parallel group 16 Emergency departments | safety | minor and transient side effects | Possible intrinsic bias |
efficacy | Median time to onset of pain relief 9mins vs 15mins SAT | ||||
user satisfaction | Staff and patients (p<0.001) | ||||
Borobia et al 2020 Spain | 305 adults over age 18 moderate to severe pain due to limb injuries (limbs, fracture, swelling, dislocation, contusion, burns, laceration) 156 methoxyflurane vs SAT | Phase 3b Randomised con-trolled trial, open label, multi-centre, active-controlled 13 Emergency departments and 1 pre-hospital setting | safety | minor and transiet | Risks participants and researchers bias Variation in SAT offered Patients in sever pain not offered opioids Funded by Multipharma |
efficacy | median time to onset of pain relief 3 mins vs 10 mins SAT | ||||
user satisfaction | Patients 77% vs 38% SAT and Clinicians 72% vs 19% SAT | ||||
overall pain reduction | -2.47 on NRS (numerical rating scale) scale at 20 mins vs 1.39 control (difference 1: CI 0.84-1.32) | ||||
Porter et al 2018 UK | 4 studies (none of which compare nitrous oxide with methoxyflurane) | Systematic litera-ture review Indirect treatment comparison level of evidence 2b | efficacy | No statistical difference at 5,10 and 15 mins | Insufficient studies Questionable methodology of the studies being analysed Multiple interventions |
Viglino et al 2019 France | 200 adults over age 18 years (median 32 years) moderate to severe pain due to minor limb trauma (fracture, contusion, sprain, wound, burn, dislocation) | Prospective, observational | safety | frequent (64%) but not serious adverse events | Observer bias, selective patients (young, benign limb trauma) Received funding from 2 Multipharma companies which market methoxyflurane |
efficacy | 66/200 had pain score <3 on NRS at 15 mins whilst overall reduction in pain over 60mins was significant (p<0.001) | ||||
user satisfaction | good level of satisfaction without statistical data | ||||
Campbell et al 2020 Canada | 49 adults over age 18 moderate to sever pain with minor limb trauma 87.8% (sprain 40.8% and fracture 32.7%) | Phase 4 real world ongoing trial prospective open label, multi centred | safety | no serious adverse events | Ongoing trial, no data in abstract regarding what rescue medication was given, no information in the abstract regarding how much improvement of pain was reported on NRS |
efficacy | 5 mins post administration methoxyflurane 80.4% pain relief 15 mins 91.3% 100% by 30mins | ||||
user satisfaction | >80% of pa-tients rated good, very good or excel-lent within 20mins post start of treat-ment | ||||
Serra et al 2020 Italy | 69 adults over age 65 years moderate to severe pain due to trauma to a single limb | Sub-group, post hoc analysis of MEDITA trial for patients >age 65 | safety | no serious adverse events | Small sample size with no power calculation Post hoc study Intrinsic bias |
efficacy | median time of pain relief 9mins vs 15mins for SAT | ||||
user satisfaction | Patients 64 %(Methoxyflu-rane) vs 6% (SAT) Clinicians (60% vs 17.7%) |